Literature DB >> 17720148

Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.

Lisa Mosconi1, Susan De Santi, Miroslaw Brys, Wai H Tsui, Elizabeth Pirraglia, Lidia Glodzik-Sobanska, Kenneth E Rich, Remigius Switalski, Pankaj D Mehta, Domenico Pratico, Ray Zinkowski, Kay Blennow, Mony J de Leon.   

Abstract

BACKGROUND: We examined whether cerebral metabolic rates for glucose (CMRglc) on 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) and cerebrospinal fluid (CSF) markers of Alzheimer's disease (AD) are altered in cognitively normal apolipoprotein E (ApoE) E4 carriers with subjective memory complaints (SMC).
METHODS: Twenty-eight middle-aged normal subjects (NL) were examined, including 13 E4 carriers (E4+; 6 with SMC [SMC+] and 7 without SMC [SMC-]) and 15 noncarriers (E4-; 7 SMC+ and 8 SMC-). Subjects received an FDG-PET scan and a lumbar puncture to measure CSF total (T-Tau) and hyperphosphorylated tau(231) (P-Tau), 40 and 42 amino acid forms of beta-amyloid (Abeta40 and Abeta42), and F(2)-isoprostane (IP).
RESULTS: As compared with E4-, E4+ subjects showed decreased CMRglc in AD-related brain regions and associated higher CSF IP, P-Tau, T-Tau, and P-Tau/Abeta42 levels (p's < .05). As compared with SMC-, SMC+ subjects showed reduced parietotemporal and parahippocampal gyrus (PHG) CMRglc. A significant ApoE by SMC status interaction was found, with the E4+/SMC+ showing the lowest PHG CMRglc and the highest CSF IP, P-Tau, and P-Tau/Abeta42 levels as compared with all other subgroups (p's < or = .05). The combination of CSF and CMRglc measures significantly improved the accuracy of either measures alone in discriminating ApoE groups (86% accuracy, odds ratio [OR] = 4.1, p < .001) and E4+/SMC+ from all other subgroups (86% accuracy, OR = 3.7, p = .005). Parahippocampal gyrus CMRglc was the most accurate discriminator of SMC groups (75% accuracy, OR = 2.4, p < .001).
CONCLUSIONS: Normal E4 carriers with SMC show altered AD-related CSF and FDG-PET measures. Longitudinal studies are needed to assess whether these brain abnormalities foreshadow clinical decline.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720148      PMCID: PMC2386268          DOI: 10.1016/j.biopsych.2007.05.030

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  58 in total

1.  Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

Authors:  P D Mehta; T Pirttilä; S P Mehta; E A Sersen; P S Aisen; H M Wisniewski
Journal:  Arch Neurol       Date:  2000-01

2.  PET of brain amyloid and tau in mild cognitive impairment.

Authors:  Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

3.  Hippocampal hypometabolism predicts cognitive decline from normal aging.

Authors:  Lisa Mosconi; Susan De Santi; Juan Li; Wai Hon Tsui; Yi Li; Madhu Boppana; Eugene Laska; Henry Rusinek; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-01-11       Impact factor: 4.673

4.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

5.  Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI.

Authors:  A J Saykin; H A Wishart; L A Rabin; R B Santulli; L A Flashman; J D West; T L McHugh; A C Mamourian
Journal:  Neurology       Date:  2006-09-12       Impact factor: 9.910

6.  The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease.

Authors:  M Bobinski; M J de Leon; J Wegiel; S Desanti; A Convit; L A Saint Louis; H Rusinek; H M Wisniewski
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

7.  Prognosis with dementia in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.

Authors:  C Jagger; K Andersen; M M Breteler; J R Copeland; C Helmer; M Baldereschi; L Fratiglioni; A Lobo; H Soininen; A Hofman; L J Launer
Journal:  Neurology       Date:  2000       Impact factor: 9.910

8.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.

Authors:  G W Small; L M Ercoli; D H Silverman; S C Huang; S Komo; S Y Bookheimer; H Lavretsky; K Miller; P Siddarth; N L Rasgon; J C Mazziotta; S Saxena; H M Wu; M S Mega; J L Cummings; A M Saunders; M A Pericak-Vance; A D Roses; J R Barrio; M E Phelps
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

9.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

Authors:  M J de Leon; S DeSanti; R Zinkowski; P D Mehta; D Pratico; S Segal; H Rusinek; J Li; W Tsui; L A Saint Louis; C M Clark; C Tarshish; Y Li; L Lair; E Javier; K Rich; P Lesbre; L Mosconi; B Reisberg; M Sadowski; J F DeBernadis; D J Kerkman; H Hampel; L-O Wahlund; P Davies
Journal:  Neurobiol Aging       Date:  2005-08-26       Impact factor: 4.673

10.  Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein E-IV genetic risk for Alzheimer disease.

Authors:  Linda Ercoli; Prabha Siddarth; Sung-Cheng Huang; Karen Miller; Susan Y Bookheimer; Benjamin C Wright; Michael E Phelps; Gary Small
Journal:  Arch Gen Psychiatry       Date:  2006-04
View more
  92 in total

Review 1.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

2.  Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies.

Authors:  Laura A Rabin; Colette M Smart; Paul K Crane; Rebecca E Amariglio; Lorin M Berman; Mercé Boada; Rachel F Buckley; Gaël Chételat; Bruno Dubois; Kathryn A Ellis; Katherine A Gifford; Angela L Jefferson; Frank Jessen; Mindy J Katz; Richard B Lipton; Tobias Luck; Paul Maruff; Michelle M Mielke; José Luis Molinuevo; Farnia Naeem; Audrey Perrotin; Ronald C Petersen; Lorena Rami; Barry Reisberg; Dorene M Rentz; Steffi G Riedel-Heller; Shannon L Risacher; Octavio Rodriguez; Perminder S Sachdev; Andrew J Saykin; Melissa J Slavin; Beth E Snitz; Reisa A Sperling; Caroline Tandetnik; Wiesje M van der Flier; Michael Wagner; Steffen Wolfsgruber; Sietske A M Sikkes
Journal:  J Alzheimers Dis       Date:  2015-09-24       Impact factor: 4.472

3.  Amyloid-β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study.

Authors:  Beth E Snitz; Oscar L Lopez; Eric McDade; James T Becker; Ann D Cohen; Julie C Price; Chester A Mathis; William E Klunk
Journal:  J Alzheimers Dis       Date:  2015-09-24       Impact factor: 4.472

4.  Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease.

Authors:  Sönke Arlt; Stefanie Brassen; Holger Jahn; Florian Wilke; Martin Eichenlaub; Ivayla Apostolova; Fabian Wenzel; Frank Thiele; Stewart Young; Ralph Buchert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-14       Impact factor: 9.236

5.  Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology.

Authors:  Lidia Glodzik; Susan De Santi; Kenneth E Rich; Miroslaw Brys; Elizabeth Pirraglia; Rachel Mistur; Remigiusz Switalski; Lisa Mosconi; Martin Sadowski; Henrik Zetterberg; Kaj Blennow; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

6.  Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly.

Authors:  Rebecca E Amariglio; Elizabeth C Mormino; Alison C Pietras; Gad A Marshall; Patrizia Vannini; Keith A Johnson; Reisa A Sperling; Dorene M Rentz
Journal:  Neurology       Date:  2015-06-05       Impact factor: 9.910

Review 7.  Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging.

Authors:  Lisa Mosconi; Valentina Berti; Lidia Glodzik; Alberto Pupi; Susan De Santi; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 8.  Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.

Authors:  Alexander Drzezga; Daniele Altomare; Cristina Festari; Javier Arbizu; Stefania Orini; Karl Herholz; Peter Nestor; Federica Agosta; Femke Bouwman; Flavio Nobili; Zuzana Walker; Giovanni Battista Frisoni; Marina Boccardi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-13       Impact factor: 9.236

Review 9.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

10.  The influence of parental history of Alzheimer's disease and apolipoprotein E epsilon4 on the BOLD signal during recognition memory.

Authors:  Guofan Xu; Donald G McLaren; Michele L Ries; Michele E Fitzgerald; Barbara B Bendlin; Howard A Rowley; Mark A Sager; Craig Atwood; Sanjay Asthana; Sterling C Johnson
Journal:  Brain       Date:  2008-10-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.